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Parkinson’s disease is the secondmost important neurodegenerative disorder worldwide. It is characterized by the presence of Lewy
bodies, which aremainly composed of𝛼-synuclein and ubiquitin-bound proteins. Both the ubiquitin proteasome system (UPS) and
autophagy-lysosomal pathway (ALS) are altered in Parkinson’s disease, leading to aggregation of proteins, particularly 𝛼-synuclein.
Interestingly, it has been observed that copper promotes the protein aggregation process. Additionally, phosphorylation of 𝛼-
synuclein along with copper also affects the protein aggregation process.The interrelation among 𝛼-synuclein phosphorylation and
its capability to interact with copper, with the subsequent disruption of the protein degradation systems in the neurodegenerative
process of Parkinson’s disease, will be analyzed in detail in this review.
1. Introduction
Parkinson’s disease (PD) is the second most frequent neu-
rodegenerative disorder related to aging worldwide [1]. The
clinical symptoms of this disease are resting tremor, rigid-
ity, bradykinesia, akinesia, postural instability, difficulty in
speech, and breathing problems [2]. Most PD cases appear
to be sporadic, and only about 5–10% of the cases are due to
genetic mutations [3]. Exposure to environmental pollutants
such as herbicides (paraquat), pesticides (rotenone), and
toxic substances during the manufacture of narcotic drugs
(MPTP+) and prolonged exposure to transition metals have
been reported to be related to sporadic cases of PD [4–
6]. PD is characterized by dopaminergic neuronal loss in
the substantia nigra at the central nervous system (CNS), a
significant reduction in dopamine levels, and the presence of
Lewy bodies [7, 8]. Lewy bodies are composed of abnormal
deposits of protein aggregates, particularly 𝛼-synuclein and
ubiquitin-bound proteins [9]. Abnormal protein aggregation
results from the UPS and ALS alteration, and the latter
includes disruption of lysosomal hydrolase trafficking [10–
12]. Interestingly, some metal ions such as copper have
shown to promote the protein aggregation process [13–15].
Additionally, phosphorylation of 𝛼-synuclein, along with
copper, accelerates the protein aggregation process [16, 17].
Therefore, in order to have a better understanding of
the mechanisms involved in the neurodegenerative process
of PD, the interrelation among 𝛼-synuclein phosphorylation
and its capability to interact with copper, as well as the
consequent disruption of the protein degradation systems,
will be analyzed in detail in this review.
2. 𝛼-Synuclein
The main histological hallmark of PD is the presence of
eosinophilic cytoplasmic inclusions known as Lewy bodies,
which are localized in the substantia nigra and are formed
mostly by𝛼-synuclein [18–20].𝛼-Synuclein is a thermostable,
preserved, and unfolded cytosolic protein [21], belonging
to a family of homologous proteins called synucleins, and
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Figure 1: Schematic structure of 𝛼-synuclein. (a) 𝛼-Synuclein mutations related to familial PD are shown as red squares. Metal-binding sites
are depicted as yellow squares. Seine (S) and threonine (Y) amino acid residues targeted by phosphorylation are indicated as blue squares. (b)
Amino acid composition of 𝛼-synuclein. Residues in blue represent copper-binding sites. Red squares indicate methionine 1 and histidine 50,
which are independent anchoring sites for copper binding. Green squares show phosphorylation sites (Y125 and S129) related to an increased
copper-binding capability.
is expressed in approximately 80% of the total area of the
human brain [22, 23]. 𝛼-Synuclein consists of 140 amino
acid residues [24] organized in three structural regions: an
amphipathic amino-terminal domain from 1 to 60 amino
acid residues, responsible for the binding of 𝛼-synuclein to
lipid vesicles [25, 26]; the NAC (non-amyloid-𝛽 component)
region from 61 to 95 amino acid residues, also found in amy-
loid plaques of patients suffering from Alzheimer’s disease
[27] and responsible for 𝛼-synuclein aggregation and 𝛽 sheets
arrangement [28]; and the carboxy-terminal domain from 96
to 140 amino acid residues, which is the main target for the
protein phosphorylation [29, 30] (Figure 1(a)). 𝛼-Synuclein
is primarily expressed in neurons at cytosolic level and is
abundant in presynaptic terminals [31]. However, it has also
been linked to synaptic vesicles, plasma membrane lipid rafts
and the nucleus [32]. Up to date, themain normal function of
𝛼-synuclein has not been well defined. 𝛼-Synuclein has been
related to different functions, including inhibition of tyro-
sine hydroxylase [33], inhibition of dopamine release [34],
dopamine uptake [35], neural plasticity, synaptic maturation
and maintenance [36–38], and v-SNARE complex assembly
[39, 40].
𝛼-Synuclein has the capability to assemble into amyloid
fibers, soluble oligomers, and/or aggregates. Once the accu-
mulation of 𝛼-synuclein surpasses its degradation rate, it
leads to the formation of Lewy bodies and the subsequent
death of dopaminergic neurons in the substantia nigra
[41]. It has been suggested that 𝛼-synuclein protofibrils are
responsible for the neurotoxic effects induced by 𝛼-synuclein
[42, 43]. Among the possible mechanisms involved in the
neurotoxicity mediated by 𝛼-synuclein are the following:
mitochondrial dysfunction, oxidative stress [44], lysosomal
leakage [45], cytoskeletal disruption [46], altered axonal
transport, and subsequent synapses dysfunction, which are
all related to neurodegeneration [47]. 𝛼-Synuclein is tar-
geted for degradation by the UPS and the ALS including
the chaperone-mediated autophagy (CMA) and macroau-
tophagy (autophagy) [48–51]. Importantly, both degradation
pathways are dysregulated or inhibited in PD [52].
The relationship between 𝛼-synuclein and PD was estab-
lished with the identification of specific mutations in the
SNCA gene encoding for 𝛼-synuclein, in families with PD.
The specific mutations identified in 𝛼-synuclein were a
substitution from alanine to threonine at amino acid residue
53 (A53T), a mutation of Greek origin [53]; a substitution
from alanine to proline at amino acid residue 30 (A30P), a
mutation of Germanic origin [54]; and a substitution from
glutamic acid to lysine at amino acid residue 46 (E46K),
a mutation of Spanish origin [55] (Figure 1(a)). Recently,
two new mutations have been identified, a substitution from
histidine to glutamine at amino acid residue 50 (H50Q) [56]
and a substitution from glycine to aspartic acid at amino
acid residue 51 (G51D), a mutation of French origin [57].
Additionally, SNCA gene duplication [58] and triplication
also occur and are related to PD [59].
3. 𝛼-Synuclein Phosphorylation in Parkinson’s
Disease: Neuroprotective or Neurotoxic?
In the aggregation process of 𝛼-synuclein, its phosphoryla-
tion plays an important role [29, 60] by directing its local-
ization and interaction [61] and by modifying its secondary
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Figure 2: Cell alterations involved in the aggregation process of 𝛼-synuclein. Damaged or unrequired proteins are regulated by both the
proteasomal and lysosomal degradation pathways. UPS disruption leads to activation of the ALS and vice versa, as a compensation
mechanism. Bothmechanisms are affected in PD, which results in protein accumulation including 𝛼-synuclein and ubiquitin-bound proteins.
Accumulation of unfolded or misfolded proteins into the endoplasmic reticulum activates the unfolded protein response. Mitochondrial
dysfunction and oxidative stress are also interrelated and linked to the pathogenesis of PD. All these alterations are associated with the
phosphorylation process of 𝛼-synuclein and increase 𝛼-synuclein oligomerization, leading to Lewy body formation and subsequent apoptotic
cell death.
and tertiary conformation [62–65]. 𝛼-Synuclein is targeted
by phosphorylation on multiple sites located at its carboxy-
terminal end (S87, S129, Y125, Y133, and Y136) [66–71]
(Figure 1). Several kinases have been linked to 𝛼-synuclein
phosphorylation, such as casein kinases 1 and 2 (CK1 and
CK2), G protein-coupled receptor kinases 2 and 5 (GRK2
and GRK5), polo-like kinase 2 (PLK2) [29, 72, 73], Fyn [74],
andmore recently serine/threonine protein kinase (LK6) and
MAP kinase-interacting kinase 2a (Mnk2a) [75].
Studies performed in cell cultures with neuronal phe-
notype have demonstrated that CK2-mediated 𝛼-synuclein
phosphorylation, particularly at S129, increases the appear-
ance of eosinophilic cytoplasmic inclusions resembling the
Lewy bodies of PD [76]. A major component of these
inclusions consists of C-terminally truncated 𝛼-synuclein,
and lysosomal proteases, such as cathepsin D, may be
involved in its production for 𝛼-synuclein oligomerization
[77]. Somemechanisms are triggered by the phosphorylation
of 𝛼-synuclein, including the unfolded protein response
(UPR) and disruption of lysosomal degradation pathways,
which may lead to protein aggregation and subsequently to
cell death (Figure 2) [78, 79]. Monomers and dimers of 𝛼-
synuclein are degraded by ALS, specifically, CMA [79, 80].
In addition, it has been reported that a phosphorylated-like
mutant version of 𝛼-synuclein (S129E), which mimics the
biochemical and biophysical properties of 𝛼-syn phospho-
rylation observed in PD patients’ brains [76] and remained
“phosphorylated-like” after exposure to the lysosomal frac-
tion, cannot translocate across the lysosomal membrane
probably because of a conformational change induced by its
phosphorylation, decreasing its interaction with the CMA
receptor (LAMP-2A) at the lysosomal membrane [79, 80].
In addition, dysfunctional mitochondrial metabolism
and increased ROS production are also related to the
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Figure 3: 𝛼-Synuclein-copper complex formation process. Copper can be found in living organisms in both forms, oxidized Cu2+ and reduced
Cu+, and enters into the cell as Cu+ through CTR1 and CTR2. Afterwards, copper is transported to the nuclei, endoplasmic reticulum, and
mitochondria via chaperone proteins. An overload of copper may lead to the 𝛼-synuclein-copper complex formation by three potential
mechanisms. In the first one, a single 𝛼-synuclein molecule binds to Cu2+, folding and bringing together the amino and carboxy-terminal
ends.The secondmechanism involves twomolecules of 𝛼-synuclein with a head-to-tail arrangement, generating a copper-binding site at both
ends. In the third mechanism, the carboxy-terminal region of one molecule of 𝛼-synuclein interacts with the amino-terminal region from
another molecule of 𝛼-synuclein creating a Cu2+ binding site. Next, one of the two 𝛼-synucleins interacts with a third 𝛼-synuclein molecule,
forming a second Cu2+ binding site. This process will eventually lead to 𝛼-synuclein oligomerization.
phosphorylation of 𝛼-synuclein (Figure 3) [81]. Hydrogen
peroxide- (H
2
O
2
-) induced oxidative stress increases the
phosphorylation of 𝛼-synuclein at S129 and the formation of
cytoplasmic inclusions [76]. On the other hand, some neuro-
toxins and the UPS inhibition increase the activity of GRK5
and CK2, whose interaction with Ca2+/calmodulin increases
𝛼-synuclein phosphorylation at S129 [82–84]. Rotenone,
an inhibitor of mitochondrial complex I, along with iron,
increases the levels of 𝛼-synuclein phosphorylation at S129,
by inducing ROS production in dopaminergic cells [81].
So far, the role of 𝛼-synuclein phosphorylation is contro-
versial. Some studies have shown a neuroprotective role of 𝛼-
synuclein phosphorylation at S129 by preventing the binding
of 𝛼-synuclein oligomers to membranes and, therefore, cellu-
lar disruption [85–88]. Additionally, phosphorylation at S129
blocked 𝛼-synuclein fibrillation in vitro [89]. Many studies
had focused on the role of 𝛼-synuclein phosphorylation,
specifically at S129, and also at other residues such as
S87. 𝛼-Synuclein mutant variants, capable of mimicking or
inhibiting the phosphorylation process (S129D, S129E, and
S129A), have contributed to the elucidation of its role [66,
70, 89–92]. Phosphomimicmutants S129D/E were not able to
reproduce in vitro the structural and aggregation properties
of 𝛼-synuclein. However, a nonphosphomimic mutant S129A
showed a higher protein aggregation rate and neurotoxicity
than the wild type form [70, 71, 89].
On the contrary, there is evidence showing that 𝛼-
synuclein phosphorylation at S129 induces cytotoxicity [66,
77, 93, 94]. It has been demonstrated that 𝛼-synuclein
phosphorylation at S129 mediated by CK2 is an important
factor for its protein aggregation and toxicity, inducing
UPR dysregulation, endoplasmic reticulum (ER) stress, and
apoptosis [78]. Besides, phosphorylation at S129 is essential
for interaction of 𝛼-synuclein with synphilin-1 and parkin,
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which form the ubiquitinated inclusions [76]. Recently, it has
been reported that 𝛼-synuclein can also be phosphorylated
by LK6 andMnk2a, with subsequent dopaminergic neuronal
death and formation of cytoplasmic inclusions, respectively
[75]. Nonetheless, it has been suggested that malfunction of
the UPS increases CK2 activity, resulting in hyperphospho-
rylation of the 𝛼-synuclein at S129 [95].
Approximately 90% of 𝛼-synuclein detected in Lewy
bodies from postmortem PD samples is phosphorylated at
S129. Conversely, only 4% of 𝛼-synuclein present in normal
brains is phosphorylated [66, 70, 96, 97]. Importantly, a mass
spectrometry study in human cerebrospinal fluid (CSF) of PD
and other parkinsonian disorders determined a significantly
higher concentration of phosphorylated 𝛼-synuclein at S129,
as well as a significant increase in the ratio of phosphorylated
𝛼-synuclein at S129/total 𝛼-synuclein in PD compared to
healthy controls [98]. More recently, a marked difference
between PD patients and healthy controls was observed with
a sensitive and specific Elisa test, by combining measure-
ments of total, oligomeric, and phosphorylated (S129) 𝛼-
synuclein in CSF [99].
4. Interaction of Phosphorylated 𝛼-Synuclein
with Metal Ions
Proteins are the main biomolecules affected in most patholo-
gies; posttranslational modifications of proteins suchlike oxi-
dation, nitration, carbonylation, glutathionylation, and phos-
phorylation are related to protein inactivation. Phosphory-
lated proteins have a strong binding affinity to certain metals
[16, 100, 101]. Multivalent metal ions, like manganese, cobalt,
iron, andmainly aluminum and copper, increase 𝛼-synuclein
fibril formation by inducing conformational changes [14, 102,
103]. 𝛼-Synuclein may interact with different metal ions at
either its carboxy-terminal domain or its amino-terminal
domain, depending on the metal ion concentration [13]. For
instance, at low concentrations (40–100 𝜇M) Cu2+ ion binds
to the amino-terminal domain [13, 104], while at extremely
high concentrations (0.5–5mM), which are unlikely to occur
in tissues, metal ions such as Fe2+, Mn2+, Ni2+, Co2+, and
Cu2+ bind to the carboxy-terminal domain [105]. Cu2+ ion is
a potent inducer and accelerator of 𝛼-synuclein aggregation,
linked to the carboxy-terminal domain, which is required
for its oligomerization [106]. Phosphorylation at both Y125
and S129 residues of 𝛼-synuclein, which are close to metal-
binding sites, increments Cu2+, Pb2+, and Fe2+ binding
capability to carboxy-terminal domain (Figure 1) [17, 105].
5. Copper Mediates 𝛼-Synuclein Aggregation
On the other hand, copper has the ability to inhibit the
proteasomal chymotrypsin-like peptidase activity [107]. Cop-
per enters into the cell through the copper transporters 1
and 2 (CTR1 and CTR2), which are located on the cell
membrane (Figure 3) [108]. Two regions, 1MDVFMKGLS9
and 48VVHGV52 (Figure 1), with high-affinity binding sites
for copper were identified at 𝛼-synuclein, and may be of
great biological importance in the pathogenesis of PD [104].
Within the 𝛼-synuclein sequence, methionine 1 and histidine
50 residues function as independent anchoring sites for
copper binding (Figure 1) [104, 109, 110].
There are three models that have been suggested for
copper binding to 𝛼-synuclein (Figure 3). In the first model,
a single 𝛼-synuclein molecule binds to Cu2+, folding and
bringing together the amino and carboxy-terminal regions.
The secondmodel involves twomolecules of𝛼-synucleinwith
a head-to-tail arrangement, generating a copper-binding site
at both ends. In the thirdmodel, 𝛼-synuclein oligomerization
takes place by interaction of the carboxy-terminal region of
one molecule of 𝛼-synuclein with the amino-terminal region
from a second molecule of 𝛼-synuclein originating a Cu2+
binding site; then a second Cu2+ binding site is formed by
interaction of one of the two 𝛼-synucleins with a third 𝛼-
synuclein molecule [15].
Regarding the aggregation process of 𝛼-synuclein medi-
ated by copper, two mechanisms have been proposed. In
one of them, high levels of 𝛼-synuclein-copper complexes
will cause instability of intramolecular interactions leading
to self-assembling of 𝛼-synuclein into fibrillar complexes.
In the second one, copper redox-mediated reactions induce
oxidation of 𝛼-synuclein using electron donors (NADH,
NADPH, glutathione, etc.), causing its oligomerization and
precipitation [111–114].
Environmental exposure to metal ions (e.g., zinc and
copper) induces 𝛼-synuclein aggregates and oxidative stress,
which are also associatedwith dysregulation of theUPS in PD
[82, 115, 116].
Copper plays a dual role in the neurotoxic effect of 𝛼-
synuclein. Once intracellular copper concentration is raised,
chaperone proteins (e.g., ATOX1, CCS,MT3, andCOX 17) are
in charge to uptake this metal inside the cell, but an overload
of copper might surpass the chaperone proteins available to
regulate its levels. On the other hand, mutations affecting
the ability of chaperones to bind copper might also increase
its toxic effect [117]. Subsequently, free copper binds to the
UPS to inhibit its activity; then𝛼-synuclein is phosphorylated
increasing its affinity to metals [71]. 𝛼-Synuclein-copper
complex formation alters cell redox signaling, which results
in ROS formation including H
2
O
2
. H
2
O
2
oxidizes dopamine,
which is toxic to dopaminergic neurons [118, 119].
6. Concluding Remarks
𝛼-Synuclein is a highly relevant protein in PD etiopathology,
and since the elucidation of 𝛼-synuclein-copper interactions,
this transition metal was brought into the spotlight of neu-
rodegeneration research. Although this complex formation is
now subject of intense research,many open questions remain:
How are levels of copper regulated by 𝛼-synuclein? Does cop-
per influence 𝛼-synuclein phosphorylation and aggregation?
How important is copper and 𝛼-synuclein interaction? Can
we use phosphorylation of 𝛼-synuclein as a biomarker? Can
we exploit the inhibition of phosphorylation of 𝛼-synuclein
as a therapeutic approach? It is certain, that these therapies
need to initiate promptly in order to address pathological
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changes in a less advanced stage. Regrettably, the diagnosis of
PDnowadays is based on purely clinical signs, and these signs
aremanifestedwhenmore thanhalf of dopaminergic neurons
have died. Therefore, identification of early biomarkers such
as𝛼-synuclein phosphorylationmay be a promising approach
for diagnosis and subsequently for PD treatment and cor-
related with preclinical signs indicating incipient disease at
a nonsymptomatic stage. Since 𝛼-synuclein and copper play
such important roles in the aggregation process, a chelator
administration is currently under investigation and may be a
helpful approach against PD.
Conflicts of Interest
The authors declare that there are no conflicts of interest
regarding the publication of this paper.
Acknowledgments
This work was supported by the National Council of Sci-
ence and Technology (CONACYT) CB-2013-221615 (Aracely
Garcia-Garcia) and Program for the Professional Develop-
ment of the Professors (PRODEP)DSA/103.5/14/11175 (Hum-
berto Rodriguez-Rocha). Juan Antonio Castillo-Gonzalez
received a scholarship from CONACYT.
References
[1] K. Wirdefeldt, H. Adami, P. Cole, D. Trichopoulos, and J. Man-
del, “Epidemiology and etiology of Parkinson’s disease: a review
of the evidence,” European Journal of Epidemiology, vol. 26,
supplement 1, pp. S1–S58, 2011.
[2] L. S. Forno, “Neuropathology of Parkinson’s disease,” Journal of
Neuropathology & Experimental Neurology, vol. 55, no. 3, pp.
259–272, 1996.
[3] S. Lesage and A. Brice, “Parkinson’s disease: from monogenic
forms to genetic susceptibility factors,” Human Molecular
Genetics, vol. 18, no. R1, pp. R48–R59, 2009.
[4] B. C. L. Lai, S. A. Marion, K. Teschke, and J. K. C. Tsui,
“Occupational and environmental risk factors for Parkinson’s
disease,”Parkinsonism&RelatedDisorders, vol. 8, no. 5, pp. 297–
309, 2002.
[5] J. Peng, L. Peng, F. F. Stevenson, S. R. Doctrow, and J. K.
Andersen, “Iron and paraquat as synergistic environmental risk
factors in sporadic Parkinson’s disease accelerate age-related
neurodegeneration,”The Journal of Neuroscience, vol. 27, no. 26,
pp. 6914–6922, 2007.
[6] K. Opeskin and R. M. Anderson, “Suspected MPTP-induced
parkinsonism,” Journal of Clinical Neuroscience, vol. 4, no. 3, pp.
366–370, 1997.
[7] C. W. Shults, “Lewy bodies,” Proceedings of the National
Acadamy of Sciences of the United States of America, vol. 103, no.
6, pp. 1661–1668, 2006.
[8] O. Hornykiewicz, “The discovery of dopamine deficiency in
the parkinsonian brain,” Journal of Neural Transmission. Sup-
plementa, vol. 70, pp. 9–15, 2006.
[9] M. S. Pollanen, D. W. Dickson, and C. Bergeron, “Pathology
and biology of the lewy body,” Journal of Neuropathology &
Experimental Neurology, vol. 52, no. 3, pp. 183–191, 1993.
[10] C. Cook, C. Stetler, and L. Petrucelli, “Disruption of protein
quality control in Parkinson’s disease,” Cold Spring Harbor
Perspectives in Medicine, vol. 2, no. 5, Article ID a009423, 2012.
[11] D. Ebrahimi-Fakhari, L. Wahlster, and P. J. McLean, “Protein
degradation pathways in Parkinson’s disease: curse or blessing,”
Acta Neuropathologica, vol. 124, no. 2, pp. 153–172, 2012.
[12] J. R. Mazzulli, F. Zunke, O. Isacson, L. Studer, and D. Krainc,
“𝛼-Synuclein-induced lysosomal dysfunction occurs through
disruptions in protein trafficking in human midbrain synu-
cleinopathy models,” Proceedings of the National Acadamy of
Sciences of the United States of America, vol. 113, no. 7, pp. 1931–
1936, 2016.
[13] A. Binolfi, R. M. Rasia, C. W. Bertoncini et al., “Interaction of
𝛼-synuclein with divalent metal ions reveals key differences:
a link between structure, binding specificity and fibrillation
enhancement,” Journal of the American Chemical Society, vol.
128, no. 30, pp. 9893–9901, 2006.
[14] L. Breydo and V. N. Uversky, “Role of metal ions in aggrega-
tion of intrinsically disordered proteins in neurodegenerative
diseases,”Metallomics, vol. 3, no. 11, pp. 1163–1180, 2011.
[15] D. R. Brown, “Metal binding to alpha-synuclein peptides and its
contribution to toxicity,” Biochemical and Biophysical Research
Communications, vol. 380, no. 2, pp. 377–381, 2009.
[16] L. L. Liu and K. J. Franz, “Phosphorylation-dependent metal
binding by 𝛼-synuclein peptide fragments,” Journal of Biological
Inorganic Chemistry, vol. 12, no. 2, pp. 234–247, 2007.
[17] Y. Lu, M. Prudent, B. Fauvet, H. A. Lashuel, and H. H. Girault,
“Phosphorylation of 𝛼-synuclein at Y125 and S129 alters its
metal binding properties: implications for understanding the
role of 𝛼-synuclein in the pathogenesis of Parkinson’s disease
and related disorders,” ACS Chemical Neuroscience, vol. 2, no.
11, pp. 667–675, 2011.
[18] A. J. Hughes, S. E. Daniel, Y. Ben-Shlomo, and A. J. Lees, “The
accuracy of diagnosis of parkinsonian syndromes in a specialist
movement disorder service,” Brain, vol. 125, no. 4, pp. 861–870,
2002.
[19] P. T. Kotzbauer, J. Q. Trojanowski, and V. M.-Y. Lee, “Lewy
body pathology in Alzheimer’s disease,” Journal of Molecular
Neuroscience, vol. 17, no. 2, pp. 225–232, 2001.
[20] M. G. Spillantini, M. L. Schmidt, V. M. Lee, J. Q. Trojanowski,
R. Jakes, andM.Goedert, “𝛼-synuclein in Lewy bodies,”Nature,
vol. 388, no. 6645, pp. 839-840, 1997.
[21] M. Goedert, “Alpha-synuclein and neurodegenerative diseases,”
Nature Reviews Neuroscience, vol. 2, no. 7, pp. 492–501, 2001.
[22] E. Rockenstein, L. A. Hansen, M. Mallory, J. Q. Trojanowski, D.
Galasko, and E. Masliah, “Altered expression of the synuclein
family mRNA in Lewy body and Alzheimer’s disease,” Brain
Research, vol. 914, no. 1-2, pp. 48–56, 2001.
[23] R. Jakes, M. G. Spillantini, and M. Goedert, “Identification of
two distinct synucleins from human brain,” FEBS Letters, vol.
345, no. 1, pp. 27–32, 1994.
[24] E. H. Norris, B. I. Giasson, and V. M.-Y. Lee, “𝛼-Synuclein:
Normal Function and Role in Neurodegenerative Diseases,”
Current Topics in Developmental Biology, vol. 60, pp. 17–54,
2004.
[25] J. P. Segrest, M. K. Jones, H. De Loof, C. G. Brouillette, Y. V.
Venkatachalapathi, and G. M. Anantharamaiah, “The amphi-
pathic helix in the exchangeable apolipoproteins: a review of
secondary structure and function,” Journal of Lipid Research,
vol. 33, no. 2, pp. 141–166, 1992.
Parkinson’s Disease 7
[26] W. S. Davidson, A. Jonas, D. F. Clayton, and J. M. George,
“Stabilization of 𝛼-synuclein secondary structure upon binding
to synthetic membranes,” The Journal of Biological Chemistry,
vol. 273, no. 16, pp. 9443–9449, 1998.
[27] K. Ueda, H. Fukushima, E. Masliah et al., “Molecular cloning
of cDNA encoding an unrecognized component of amyloid
in Alzheimer disease,” Proceedings of the National Acadamy of
Sciences of theUnited States of America, vol. 90, no. 23, pp. 11282–
11286, 1993.
[28] A. M. Bodles, D. J. S. Guthrie, B. Greer, and G. Brent Irvine,
“Identification of the region of non-A𝛽 component (NAC) of
Alzheimer’s disease amyloid responsible for its aggregation and
toxicity,” Journal of Neurochemistry, vol. 78, no. 2, pp. 384–395,
2001.
[29] M. Okochi, J. Walter, A. Koyama et al., “Constitutive phospho-
rylation of the Parkinson’s disease associated 𝛼- synuclein,”The
Journal of Biological Chemistry, vol. 275, no. 1, pp. 390–397, 2000.
[30] M. P. Sang, Y. J. Han, T. D. Kim, H. P. Jeon, C.-H. Yang, and
J. Kim, “Distinct roles of the N-terminal-binding domain and
the C-terminal-solubilizing domain of 𝛼-synuclein, amolecular
chaperone,”The Journal of Biological Chemistry, vol. 277, no. 32,
pp. 28512–28520, 2002.
[31] D. F. Clayton and J. M. George, “The synucleins: a family of
proteins involved in synaptic function, plasticity, neurodegen-
eration and disease,” Trends in Neurosciences, vol. 21, no. 6, pp.
249–254, 1998.
[32] M. C. Bennett, “The role of 𝛼-synuclein in neurodegenerative
diseases,” Pharmacology &Therapeutics, vol. 105, no. 3, pp. 311–
331, 2005.
[33] R. G. Perez, J. C. Waymire, E. Lin, J. J. Liu, F. Guo, and M.
J. Zigmond, “A role for alpha-synuclein in the regulation of
dopamine biosynthesis,”The Journal of Neuroscience, vol. 22, pp.
3090–3099, 2002.
[34] K. E. Larsen, Y. Schmitz, M. D. Troyer et al., “𝛼-Synuclein over-
expression in PC12 and chromaffin cells impairs catecholamine
release by interfering with a late step in exocytosis,”The Journal
of Neuroscience, vol. 26, no. 46, pp. 11915–11922, 2006.
[35] C. Wersinger and A. Sidhu, “Disruption of the interaction of 𝛼-
synuclein with microtubules enhances cell surface recruitment
of the dopamine transporter,” Biochemistry, vol. 44, no. 41, pp.
13612–13624, 2005.
[36] D. E. Cabin, K. Shimazu, D. Murphy et al., “Synaptic vesicle
depletion correlates with attenuated synaptic responses to
prolonged repetitive stimulation in mice lacking 𝛼-synuclein,”
The Journal of Neuroscience, vol. 22, no. 20, pp. 8797–8807, 2002.
[37] W. Dauer, N. Kholodilov, M. Vila et al., “Resistance of 𝛼-
synuclein null mice to the parkinsonian neurotoxin MPTP,”
Proceedings of the National Acadamy of Sciences of the United
States of America, vol. 99, no. 22, pp. 14524–14529, 2002.
[38] A. Abeliovich, Y. Schmitz, I. Farin˜as et al., “Mice lacking
𝛼-synuclein display functional deficits in the nigrostriatal
dopamine system,” Neuron, vol. 25, no. 1, pp. 239–252, 2000.
[39] N. M. Bonini and B. I. Giasson, “Snaring the function of 𝛼-
synuclein,” Cell, vol. 123, no. 3, pp. 359–361, 2005.
[40] J. Burre´, M. Sharma, T. Tsetsenis, V. Buchman, M. R. Etherton,
and T. C. Su¨dhof, “𝛼-Synuclein promotes SNARE-complex
assembly in vivo and in vitro,” Science, vol. 329, no. 5999, pp.
1663–1667, 2010.
[41] J. E.Duda,V.M.-Y. Lee, and J.Q. Trojanowski, “Neuropathology
of synuclein aggregates: New insights into mechanisms of
neurodegenerative diseases,” Journal of Neuroscience Research,
vol. 61, no. 2, pp. 121–127, 2000.
[42] R. A. Fredenburg, C. Rospigliosi, R. K.Meray et al., “The impact
of the E46K mutation on the properties of 𝛼-synuclein in its
monomelic and oligomeric states,” Biochemistry, vol. 46, no. 24,
pp. 7107–7118, 2007.
[43] M. Periquet, T. Fulga, L.Myllykangas,M.G. Schlossmacher, and
M. B. Feany, “Aggregated 𝛼-synuclein mediates dopaminergic
neurotoxicity in vivo,” The Journal of Neuroscience, vol. 27, no.
12, pp. 3338–3346, 2007.
[44] L. J. Hsu, Y. Sagara, A. Arroyo et al., “alpha-synuclein promotes
mitochondrial deficit and oxidative stress,”The American Jour-
nal of Pathology, vol. 157, no. 2, pp. 401–410, 2000.
[45] M. Hashimoto, K. Kawahara, P. Bar-On, E. Rockenstein, L.
Crews, and E. Masliah, “The role of 𝛼-synuclein assembly and
metabolism in the pathogenesis of Lewy body disease,” Journal
of Molecular Neuroscience, vol. 24, no. 3, pp. 343–352, 2004.
[46] M. A. Alim, Q.-L.Ma, K. Takeda et al., “Demonstration of a role
for 𝛼-synuclein as a functionalmicrotubule-associated protein,”
Journal of Alzheimer’s Disease, vol. 6, no. 4, pp. 435–442, 2004.
[47] D. A. Scott, I. Tabarean, Y. Tang, A. Cartier, E. Masliah, and
S. Roy, “A pathologic cascade leading to synaptic dysfunction
in 𝛼-synuclein-induced neurodegeneration,” The Journal of
Neuroscience, vol. 30, no. 24, pp. 8083–8095, 2010.
[48] F. Yang, Y.-P. Yang, C.-J. Mao et al., “Crosstalk between the
proteasome system and autophagy in the clearance of 𝛼-
synuclein,” Acta Pharmacologica Sinica, vol. 34, no. 5, pp. 674–
680, 2013.
[49] Y. Machiya, S. Hara, S. Arawaka et al., “Phosphorylated 𝛼-
Synuclein at Ser-129 is targeted to the proteasome pathway
in a ubiquitin-independent manner,” The Journal of Biological
Chemistry, vol. 285, no. 52, pp. 40732–40744, 2010.
[50] T. Vogiatzi, M. Xilouri, K. Vekrellis, and L. Stefanis, “Wild type
𝛼-synuclein is degraded by chaperone-mediated autophagy and
macroautophagy in neuronal cells,” The Journal of Biological
Chemistry, vol. 283, no. 35, pp. 23542–23556, 2008.
[51] A. M. Cuervo, L. Stafanis, R. Fredenburg, P. T. Lansbury, and
D. Sulzer, “Impaired degradation of mutant 𝛼-synuclein by
chaperone-mediated autophagy,” Science, vol. 305, no. 5688, pp.
1292–1295, 2004.
[52] J. L. Webb, B. Ravikumar, J. Atkins, J. N. Skepper, and D. C.
Rubinsztein, “𝛼-Synuclein is degraded by both autophagy and
the proteasome,” The Journal of Biological Chemistry, vol. 278,
no. 27, pp. 25009–25013, 2003.
[53] M. H. Polymeropoulos, C. Lavedan, E. Leroy et al., “Mutation
in the 𝛼-synuclein gene identified in families with Parkinson’s
disease,” Science, vol. 276, no. 5321, pp. 2045–2047, 1997.
[54] R. Kru¨ger, W. Kuhn, T. Mu¨ller et al., “Ala30Pro mutation in
the gene encoding 𝛼-synuclein in Parkinson’s disease,” Nature
Genetics, vol. 18, no. 2, pp. 106–108, 1998.
[55] J. J. Zarranz, J. Alegre, J. C. Go´mez-Esteban et al., “The new
mutation, E46K, of 𝛼-synuclein causes Parkinson and Lewy
body dementia,”Annals of Neurology, vol. 55, no. 2, pp. 164–173,
2004.
[56] S. Appel-Cresswell, C. Vilarino-Guell, M. Encarnacion et al.,
“Alpha-synuclein p.H50Q, a novel pathogenic mutation for
Parkinson’s disease,”Movement Disorders, vol. 28, no. 6, pp. 811–
813, 2013.
[57] S. Lesage, M. Anheim, F. Letournel et al., “G51D 𝛼-synuclein
mutation causes a novel Parkinsonian-pyramidal syndrome,”
Annals of Neurology, vol. 73, no. 4, pp. 459–471, 2013.
[58] M. Chartier-Harlin, J. Kachergus, C. Roumier et al., “𝛼-synu-
clein locus duplication as a cause of familial Parkinson’s disease,”
The Lancet, vol. 364, no. 9440, pp. 1167–1169, 2004.
8 Parkinson’s Disease
[59] A. B. Singleton, M. Farrer, J. Johnson et al., “𝛼-synuclein locus
triplication causes Parkinson’s disease,” Science, vol. 302, no.
5646, article 841, 2003.
[60] J. P. Anderson, D. E. Walker, J. M. Goldstein et al., “Phospho-
rylation of Ser-129 is the dominant pathological modification
of 𝛼-synuclein in familial and sporadic lewy body disease,”The
Journal of Biological Chemistry, vol. 281, no. 40, pp. 29739–
29752, 2006.
[61] T. Hunter, “Signaling—2000 and beyond,” Cell, vol. 100, no. 1,
pp. 113–127, 2000.
[62] A. A. Bielska and N. J. Zondlo, “Hyperphosphorylation of tau
induces local polyproline II helix,” Biochemistry, vol. 45, no. 17,
pp. 5527–5537, 2006.
[63] N. Errington andA. J. Doig, “A phosphoserine-lysine salt bridge
within an 𝛼-helical peptide, the strongest 𝛼-helix side-chain
interaction measured to date,” Biochemistry, vol. 44, no. 20, pp.
7553–7558, 2005.
[64] R. S. Signarvic andW. F.DeGrado, “Denovo design of amolecu-
lar switch: Phosphorylation-dependent association of designed
peptides,” Journal of Molecular Biology, vol. 334, no. 1, pp. 1–12,
2003.
[65] A.Tholey, A. Lindemann, V. Kinzel, and J. Reed, “Direct effects
of phosphorylation on the preferred backbone conformation
of peptides: A nuclear magnetic resonance study,” Biophysical
Journal, vol. 76, no. 1 I, pp. 76–87, 1999.
[66] L. Chen and M. B. Feany, “𝛼-synuclein phosphorylation con-
trols neurotoxicity and inclusion formation in a Drosophila
model of Parkinson disease,” Nature Neuroscience, vol. 8, no. 5,
pp. 657–663, 2005.
[67] B.-H. Ahn, H. Rhim, Y.-M. S. Shi Yeon Kim et al., “𝛼-
synuclein interacts with phospholipase D isozymes and inhibits
pervanadate-induced phospholipase d activation in human
embryonic kidney-293 cells,” The Journal of Biological Chem-
istry, vol. 277, no. 14, pp. 12334–12342, 2002.
[68] T. Nakamura, H. Yamashita, T. Takahashi, and S. Nakamura,
“Activated Fyn phosphorylates 𝛼-synuclein at tyrosine residue
125,” Biochemical and Biophysical Research Communications,
vol. 280, no. 4, pp. 1085–1092, 2001.
[69] C. E. Ellis, P. L. Schwartzberg, T. L. Grider, D.W. Fink, and R. L.
Nussbaum, “𝛼-Synuclein Is Phosphorylated by Members of the
Src Family of Protein-tyrosineKinases,”The Journal of Biological
Chemistry, vol. 276, no. 6, pp. 3879–3884, 2001.
[70] H. Sato, S. Arawaka, S. Hara et al., “Authentically phosphory-
lated 𝛼-synuclein at Ser129 accelerates neurodegeneration in
a rat model of familial Parkinson’s disease,” The Journal of
Neuroscience, vol. 31, no. 46, pp. 16884–16894, 2011.
[71] H. Sato, T. Kato, and S. Arawaka, “The role of Ser129 phosphory-
lation of 𝛼-synuclein in neurodegeneration of Parkinson’s dis-
ease: A review of in vivo models,” Reviews in the Neurosciences,
vol. 24, no. 2, pp. 115–123, 2013.
[72] K. J. Inglis, D. Chereau, E. F. Brigham et al., “Polo-like kinase
2 (PLK2) phosphorylates 𝛼-synuclein at serine 129 in central
nervous system,” The Journal of Biological Chemistry, vol. 284,
no. 5, pp. 2598–2602, 2009.
[73] A. N. Pronin, A. J. Morris, A. Surguchov, and J. L. Benovic,
“Synucleins are a novel class of substrates for G protein-coupled
receptor kinases,” The Journal of Biological Chemistry, vol. 275,
no. 34, pp. 26515–26522, 2000.
[74] J. Kosten, A. Binolfi, M. Stuiver et al., “Efficient modification
of alpha-synuclein serine 129 by protein kinase CK1 requires
phosphorylation of tyrosine 125 as a priming event,” ACS
Chemical Neuroscience, vol. 5, no. 12, pp. 1203–1208, 2014.
[75] S. Zhang, J. Xie, Y. Xia et al., “LK6/Mnk2a is a new kinase
of alpha synuclein phosphorylation mediating neurodegener-
ation,” Scientific Reports, vol. 5, Article ID 12564, 2015.
[76] W. W. Smith, R. L. Margolis, X. Li et al., “𝛼-synuclein phospho-
rylation enhances eosinophilic cytoplasmic inclusion formation
in SH-SY5Y cells,” The Journal of Neuroscience, vol. 25, no. 23,
pp. 5544–5552, 2005.
[77] M. Takahashi, L.-W. Ko, J. Kulathingal, P. Jiang, D. Sevlever,
and S.-H. C. Yen, “Oxidative stress-induced phosphorylation,
degradation and aggregation of𝛼-synuclein are linked to upreg-
ulated CK2 and cathepsin D,” European Journal of Neuroscience,
vol. 26, no. 4, pp. 863–874, 2007.
[78] N. Sugeno, A. Takeda, T. Hasegawa et al., “Serine 129 phos-
phorylation of 𝛼-synuclein induces unfolded protein response-
mediated cell death,” The Journal of Biological Chemistry, vol.
283, no. 34, pp. 23179–23188, 2008.
[79] M.Martinez-Vicente, Z. Talloczy, S. Kaushik et al., “Dopamine-
modified 𝛼-synuclein blocks chaperone-mediated autophagy,”
The Journal of Clinical Investigation, vol. 118, no. 2, pp. 777-778,
2008.
[80] S. K. Mak, A. L. McCormack, A. B. Manning-Bog, A. M.
Cuervo, and D. A. Di Monte, “Lysosomal degradation of 𝛼-
synuclein in vivo,”The Journal of Biological Chemistry, vol. 285,
no. 18, pp. 13621–13629, 2010.
[81] R. Perfeito, D. F. La´zaro, T. F. Outeiro, and A. C. Rego, “Linking
alpha-synuclein phosphorylation to reactive oxygen species
formation and mitochondrial dysfunction in SH-SY5Y cells,”
Molecular and Cellular Neuroscience, vol. 62, pp. 51–59, 2014.
[82] K.-Y. Chau, H. L. Ching, A. H. V. Schapira, and J. M. Cooper,
“Relationship between alpha synuclein phosphorylation, pro-
teasomal inhibition and cell death: Relevance to Parkinson’s
disease pathogenesis,” Journal of Neurochemistry, vol. 110, no. 3,
pp. 1005–1013, 2009.
[83] A. N. Pronin, C. V. Carman, and J. L. Benovic, “Structure-
function analysis of G protein-coupled receptor kinase-5: Role
of the carboxyl terminus in kinase regulation,” The Journal of
Biological Chemistry, vol. 273, no. 47, pp. 31510–31518, 1998.
[84] T. T. Chuang, L. Paolucci, and A. De Blasi, “Inhibition of
G protein-coupled receptor kinase subtypes by Ca2+/calmod-
ulin,” The Journal of Biological Chemistry, vol. 271, no. 45, pp.
28691–28696, 1996.
[85] G. S. Nu¨bling, J. Levin, B. Bader et al., “Modelling Ser129
phosphorylation inhibits membrane binding of pore-forming
alpha-synuclein oligomers,” PLoS ONE, vol. 9, no. 6, Article ID
e98906, 2014.
[86] T. Kuwahara, R. Tonegawa, G. Ito, S. Mitani, and T. Iwatsubo,
“Phosphorylation of𝛼-synuclein protein at ser-129 reduces neu-
ronal dysfunction by lowering its membrane binding property
in Caenorhabditis elegans,”The Journal of Biological Chemistry,
vol. 287, no. 10, pp. 7098–7109, 2012.
[87] V. Sancenon, S.-A. Lee, C. Patrick et al., “Suppression of 𝛼-
synuclein toxicity and vesicle trafficking defects by phospho-
rylation at S129 in yeast depends on genetic context,” Human
Molecular Genetics, vol. 21, no. 11, Article ID dds058, pp. 2432–
2449, 2012.
[88] B. Wu, Q. Liu, C. Duan et al., “Phosphorylation of 𝛼-synuclein
upregulates tyrosine hydroxylase activity in MN9D cells,” Acta
Histochemica, vol. 113, no. 1, pp. 32–35, 2011.
[89] K. E. Paleologou, A. W. Schmid, C. C. Rospigliosi et al., “Phos-
phorylation at Ser-129 but not the phosphomimics S129E/D
inhibits the fibrillation of 𝛼-synuclein,”The Journal of Biological
Chemistry, vol. 283, no. 24, pp. 16895–16905, 2008.
Parkinson’s Disease 9
[90] N. R. McFarland, Z. Fan, K. Xu et al., “𝛼-Synuclein S129
phosphorylation mutants do not alter nigrostriatal toxicity in
a rat model of parkinson disease,” Journal of Neuropathology &
Experimental Neurology, vol. 68, no. 5, pp. 515–524, 2009.
[91] O. S. Gorbatyuk, S. Li, L. F. Sullivan et al., “The phosphorylation
state of Ser-129 in human 𝛼-synuclein determines neurodegen-
eration in a rat model of Parkinson disease,” Proceedings of the
National Acadamy of Sciences of the United States of America,
vol. 105, no. 2, pp. 763–768, 2008.
[92] K. E. Paleologou, A. Oueslati, G. Shakked et al., “Phospho-
rylation at S87 is enhanced in synucleinopathies, inhibits 𝛼-
synuclein oligomerization, and influences synuclein-membrane
interactions,” The Journal of Neuroscience, vol. 30, no. 9, pp.
3184–3198, 2010.
[93] M. Yamada, T. Iwatsubo, Y. Mizuno, and H. Mochizuki, “Over-
expression of 𝛼-synuclein in rat substantia nigra results in loss
of dopaminergic neurons, phosphorylation of 𝛼-synuclein and
activation of caspase-9: Resemblance to pathogenetic changes
in Parkinson’s disease,” Journal of Neurochemistry, vol. 91, no. 2,
pp. 451–461, 2004.
[94] A. L. McCormack, S. K. Mak, and D. A. Di Monte, “Increased
a-synuclein phosphorylation and nitration in the aging primate
substantia nigra,” Cell Death & Disease, vol. 3, no. 5, article no.
e315, 2012.
[95] E. A. Waxman and B. I. Giasson, “Specificity and regulation
of casein kinase-mediated phosphorylation of 𝛼-synuclein,”
Journal of Neuropathology & Experimental Neurology, vol. 67,
no. 5, pp. 402–416, 2008.
[96] H. Fujiwara, M. Hasegawa, N. Dohmae et al., “𝛼-synuclein
is phosphorylated in synucleinopathy lesions,” Nature Cell
Biology, vol. 4, no. 2, pp. 160–164, 2002.
[97] M. Hasegawa, H. Fujiwara, T. Nonaka et al., “Phosphorylated
𝛼-synuclein is ubiquitinated in 𝛼-synucleinopathy lesions,”The
Journal of Biological Chemistry, vol. 277, no. 50, pp. 49071–
49076, 2002.
[98] Y. Wang, M. Shi, and K. A. Chung, “Phosphorylated 𝛼-
synuclein in Parkinson’s disease,” Science Translational Medi-
cine, vol. 4, no. 121, Article ID 121ra20, 2012.
[99] N. K. Majbour, N. N. Vaikath, K. D. Van Dijk et al., “Oligomeric
and phosphorylated alpha-synuclein as potential CSF biomark-
ers for Parkinson’s disease,” Molecular Neurodegeneration, vol.
11, no. 1, article no. 7, 2016.
[100] L. L. Liu and K. J. Franz, “Phosphorylation of an 𝛼-synuclein
peptide fragment enhances metal binding,” Journal of the
American Chemical Society, vol. 127, no. 27, pp. 9662-9663, 2005.
[101] A. Garcia-Garcia, H. Rodriguez-Rocha, N. Madayiputhiya, A.
Pappa,M. I. Panayiotidis, andR. Franco, “Biomarkers of protein
oxidation in human disease,” Current Molecular Medicine, vol.
12, no. 6, pp. 681–697, 2012.
[102] A. Santner and V. N. Uversky, “Metalloproteomics and metal
toxicology of 𝛼-synuclein,” Metallomics, vol. 2, no. 6, pp. 378–
392, 2010.
[103] V. N. Uversky, J. Li, and A. L. Fink, “Metal-triggered struc-
tural transformations, aggregation, and fibrillation of human
𝛼-synuclein: A possible molecular link between parkinson’s
disease and heavy metal exposure,” The Journal of Biological
Chemistry, vol. 276, no. 47, pp. 44284–44296, 2001.
[104] R. M. Rasia, C. W. Bertoncini, D. Marsh et al., “Structural
characterization of copper(II) binding to 𝛼-synuclein: insights
into the bioinorganic chemistry of Parkinson’s disease,”Proceed-
ings of the National Acadamy of Sciences of the United States of
America, vol. 102, no. 12, pp. 4294–4299, 2005.
[105] A. Binolfi, L. Quintanar, C.W. Bertoncini, C. Griesinger, and C.
O. Ferna´ndez, “Bioinorganic chemistry of copper coordination
to alpha-synuclein: Relevance to Parkinson’s disease,”Coordina-
tion Chemistry Reviews, vol. 256, no. 19-20, pp. 2188–2201, 2012.
[106] S. R. Paik, H.-J. Shin, J.-H. Lee, C.-S. Chang, and J. Kim,
“Copper(II)-induced self-oligomerization of 𝛼-synuclein,” Bio-
chemical Journal, vol. 340, no. 3, pp. 821–828, 1999.
[107] Y. Xiao, D. Chen, X. Zhang et al., “Molecular study on copper-
mediated tumor proteasome inhibition and cell death,” Interna-
tional Journal of Oncology, vol. 37, pp. 81–87, 2010.
[108] N. K. Y. Wee, D. C. Weinstein, S. T. Fraser, and S. J. Assinder,
“The mammalian copper transporters CTR1 and CTR2 and
their roles in development and disease,” The International
Journal of Biochemistry & Cell Biology, vol. 45, no. 5, pp. 960–
963, 2013.
[109] A. Binolfi, G. R. Lamberto, R. Duran et al., “Site-specific
interactions of Cu(II) with 𝛼 and 𝛽-synuclein: Bridging the
molecular gap betweenmetal binding and aggregation,” Journal
of the American Chemical Society, vol. 130, no. 35, pp. 11801–
11812, 2008.
[110] A. Binolfi, E. E. Rodriguez, D. Valensin et al., “Bioinorganic
chemistry of Parkinson’s disease: Structural determinants for
the copper-mediated amyloid formation of alpha-synuclein,”
Inorganic Chemistry, vol. 49, no. 22, pp. 10668–10679, 2010.
[111] H. R. Lucas and J. C. Lee, “Copper(ii) enhances membrane-
bound 𝛼-synuclein helix formation,” Metallomics, vol. 3, no. 3,
pp. 280–283, 2011.
[112] T. Kowalik-Jankowska, A. Rajewska, E. Jankowska, and Z.
Grzonka, “Products of Cu(II)-catalyzed oxidation of 𝛼-
synuclein fragments containing M1-D2 and H50 residues in
the presence of hydrogen peroxide,” Dalton Transactions, no. 6,
pp. 832–838, 2008.
[113] L. Guilloreau, S. Combalbert,M. Sournia-Saquet, H.Mazarguil,
and P. Faller, “Redox chemistry of copper-amyloid-𝛽: The gen-
eration of hydroxyl radical in the presence of ascorbate is linked
to redox-potentials and aggregation state,” ChemBioChem, vol.
8, no. 11, pp. 1317–1325, 2007.
[114] T. Kowalik-Jankowska, A. Rajewska, E. Jankowska, and Z.
Grzonka, “Copper(II) binding by fragments of𝛼-synuclein con-
tainingM 1-D2- and -H50-residues; a combined potentiometric
and spectroscopic study,”Dalton Transactions, no. 42, pp. 5068–
5076, 2006.
[115] P. Jenner, “Oxidative stress in Parkinson’s disease,” Annals of
Neurology, vol. 53, supplement 3, pp. S26–S38, 2003.
[116] H. Snyder, K. Mensah, C. Hsu et al., “𝛽-Synuclein reduces
proteasomal inhibition by𝛼-synuclein but not 𝛾-synuclein,”The
Journal of Biological Chemistry, vol. 280, no. 9, pp. 7562–7569,
2005.
[117] S. Montes, S. Rivera-Mancia, A. Diaz-Ruiz, L. Tristan-Lopez,
and C. Rios, “Copper and copper proteins in Parkinson’s
disease,” Oxidative Medicine and Cellular Longevity, vol. 2014,
Article ID 147251, 2014.
[118] M. E. Rice and I. Russo-Menna, “Differential compartmental-
ization of brain ascorbate and glutathione between neurons and
glia,” Neuroscience, vol. 82, no. 4, pp. 1213–1223, 1997.
[119] J. Sian, D. T. Dexter, A. J. Lees et al., “Alterations in glutathione
levels in Parkinson’s disease and other neurodegenerative disor-
ders affecting basal ganglia,” Annals of Neurology, vol. 36, no. 3,
pp. 348–355, 1994.
Submit your manuscripts at
https://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
